How to buy China Pharma stock | $0.5721

China Pharma Holdings Inc is a drug manufacturers-specialty & generic business based in the US. China Pharma shares (CPHI) are listed on the NYSE MKT and all prices are listed in US Dollars. China Pharma employs 237 staff and has a trailing 12-month revenue of around 0.00.

China Pharma stock price (NYSE MKT: CPHI)

Use our graph to track the performance of CPHI stocks over time.

China Pharma shares at a glance

• Key figures

Information last updated 2021-10-18.

Latest market close	$0.57
52-week range	$0.37 - $1.63
50-day moving average	$0.60
200-day moving average	$0.70
Wall St. target price	$3.00
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.09

Buy China Pharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy China Pharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

China Pharma price performance over time

Historical closes compared with the close of $0.5721 from 2021-10-20

1 week (2021-10-14)	4.02%
1 month (2021-09-21)	-3.03%
3 months (2021-07-21)	-20.54%
6 months (2021-04-21)	-20.54%

1 year (2020-10-21)	15.20%
2 years (2019-10-21)	120.12%
3 years (2018-10-19)	32.74%
5 years (2016-10-21)	169.35%

Is China Pharma under- or over-valued?

Valuing China Pharma stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of China Pharma's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

China Pharma's EBITDA

China Pharma's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $48,255.

The EBITDA is a measure of a China Pharma's overall financial performance and is widely used to measure a its profitability.

China Pharma financials

Revenue TTM	$10.1 million
Gross profit TTM	$2 million
Return on assets TTM	-10.16%
Return on equity TTM	-51.08%
Profit margin	-37.71%
Book value	$0.14
Market capitalisation	$24 million

TTM: trailing 12 months

Shorting China Pharma shares

There are currently 204,951 China Pharma shares held short by investors – that's known as China Pharma's "short interest". This figure is 5.7% down from 217,385 last month.

There are a few different ways that this level of interest in shorting China Pharma shares can be evaluated.

China Pharma's "short interest ratio" (SIR)

China Pharma's "short interest ratio" (SIR) is the quantity of China Pharma shares currently shorted divided by the average quantity of China Pharma shares traded daily (recently around 280754.79452055). China Pharma's SIR currently stands at 0.73. In other words for every 100,000 China Pharma shares traded daily on the market, roughly 730 shares are currently held short.

However China Pharma's short interest can also be evaluated against the total number of China Pharma shares, or, against the total number of tradable China Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case China Pharma's short interest could be expressed as 0% of the outstanding shares (for every 100,000 China Pharma shares in existence, roughly 0 shares are currently held short) or 0.01% of the tradable shares (for every 100,000 tradable China Pharma shares, roughly 10 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against China Pharma.

Find out more about how you can short China Pharma stock.

China Pharma share dividends

We're not expecting China Pharma to pay a dividend over the next 12 months.

Have China Pharma's shares ever split?

China Pharma's shares were split on a 1000:21804 basis on 14 August 2003. So if you had owned 21804 shares the day before before the split, the next day you'd have owned 1000 shares. This wouldn't directly have changed the overall worth of your China Pharma shares – just the quantity. However, indirectly, the new 2080.4% higher share price could have impacted the market appetite for China Pharma shares which in turn could have impacted China Pharma's share price.

China Pharma share price volatility

Over the last 12 months, China Pharma's shares have ranged in value from as little as $0.37 up to $1.63. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while China Pharma's is 0.2011. This would suggest that China Pharma's shares are less volatile than average (for this exchange).

China Pharma overview

China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products primarily to hospitals and private retailers in the People's Republic of China. The company offers products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate and Ozagrel Sodium to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide to treat edema diseases; and Candesartan for hypertension. It also provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. In addition, the company offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Further, it provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks.

Frequently asked questions

What percentage of China Pharma is owned by insiders or institutions?
Currently 53.058% of China Pharma shares are held by insiders and 2.599% by institutions. How many people work for China Pharma?
Latest data suggests 237 work at China Pharma. When does the fiscal year end for China Pharma?
China Pharma's fiscal year ends in December. Where is China Pharma based?
China Pharma's address is: No. 17, Jinpan Road, Haikou, China, 570216 What is China Pharma's ISIN number?
China Pharma's international securities identification number is: US16941T1043 What is China Pharma's CUSIP number?
China Pharma's Committee on Uniform Securities Identification Procedures number is: 16890J107